Reduction of oral bioavailability of lignocaine by induction of first pass metabolism in epileptic patients.

E. Perucca, A. Richens

Research output: Contribution to journalArticle

Abstract

1. The pharmacokinetics of lignocaine following single oral and intravenous doses have been investigated in six normal volunteers and in six patients receiving chronic antiepileptic drug therapy. 2. After intravenous administration, serum lignocaine levels declined biexponentially in all subjects. The serum clearance (mean +/‐ s.d.) was slightly higher in the patients (0.85 +/‐ 0.09 v 0.77 +/‐ 0.07 l/min) but the difference was not statistically significant. 3. Lignocaine bioavailability after oral administration was more than two‐ fold in the patients than in the normal subjects (0.15 +/‐ 0.06 v 0.37 +/‐ 0.09, P <0.001). 4. It is suggested that the reduced bioavailability of lignocaine in the patients is a consequence of stimulation of hepatic first‐pass metabolism by antiepileptic drugs. 1979 Blackwell Science Ltd

Original languageEnglish
Pages (from-to)21-31
Number of pages11
JournalBritish Journal of Clinical Pharmacology
Volume8
Issue number1
DOIs
Publication statusPublished - 1979

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Pharmacology, Toxicology and Pharmaceutics(all)

Fingerprint Dive into the research topics of 'Reduction of oral bioavailability of lignocaine by induction of first pass metabolism in epileptic patients.'. Together they form a unique fingerprint.

  • Cite this